Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration granted BOLD-100 an Orphan Drug Designation (ODD) in the treatment of gastric (stomach) cancer.
BioSpace takes a look at Series A financing rounds for several biotech companies: San Francisco-based Esker Therapeutics; England’s Mogrify Limited; Duke University spinout Isolere Bio; and Sunnyvale, California-based BridGene Biosciences.
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
Thousand Oaks, California-based Amgen is acquiring Seattle-based Rodeo Therapeutics, which develops small-molecule drugs that promote regeneration and repair of various tissues.
According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
Texas-based Molecular Templates (MTEM) and Bristol Myers Squibb forged a strategic research collaboration worth a potential $1.3 billion to discover and develop multiple oncology therapies using a next-generation engineered toxin body platform.
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Roche company Genentech to identify and advance novel RNA-targeted small molecule therapeutics.
Shares of Aprea Therapeutics plunged after the Boston-based company announced a late-stage cancer combination treatment failed to meet the primary endpoint of complete remission rate.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.